Atara Biotherapeutics Inc. [ATRA] Insider Activity: An Update for Investors


In a filing, Atara Biotherapeutics Inc. revealed its President and CEO Touchon Pascal unloaded Company’s shares for reported $50835.0 on Aug 16. In the deal valued at $1.65 per share,30,766 shares were sold. As a result of this transaction, Touchon Pascal now holds 675,905 shares worth roughly $ 1.03 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Nguyen AnhCo sold 15,126 shares, generating $24,997 in total proceeds. Upon selling the shares at $1.65, the EVP, Chief Sci. & Tech Officer now owns 285,999 shares.

Before that, Murugan Amar sold 8,672 shares. Atara Biotherapeutics Inc. shares valued at $14,330 were divested by the EVP, Chief Legal Officer at a price of $1.65 per share. As a result of the transaction, Murugan Amar now holds 265,391 shares, worth roughly $0.4 million.

Citigroup downgraded its Atara Biotherapeutics Inc. [ATRA] rating to a Sell from a a Neutral in a research note published on Monday, July 20, 2022; the price target was decreased to $3 from $8. PT values the company’s stock at a premium of 49.33 to its Monday closing price.

Price Performance Review of ATRA

On Monday, Atara Biotherapeutics Inc. [NASDAQ:ATRA] saw its stock jump 7.04% to $1.52. On the same session, the stock had its day’s lowest price of $1.43, but rose to a high of $1.54. Over the last five days, the stock has gained 7.80%. Atara Biotherapeutics Inc. shares have fallen nearly -53.66% since the year began. Nevertheless, the stocks have fallen -66.67% over the past one year. While a 52-week high of $5.64 was reached on 02/06/23, a 52-week low of $1.25 was recorded on 08/21/23. SMA at 50 days reached $1.8742, while 200 days put it at $3.0179. A total of 0.75 million shares were traded, compared to the trading of 0.77 million shares in the previous session.

Levels Of Support And Resistance For ATRA Stock

The 24-hour chart illustrates a support level at 1.4533, which if violated will result in even more drops to 1.3867. On the upside, there is a resistance level at 1.5633. A further resistance level may holdings at 1.6067. The Relative Strength Index (RSI) on the 14-day chart is 40.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2029, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.77%. Stochastics %K at 20.58% indicates the stock is a holding.

How much short interest is there in Atara Biotherapeutics Inc.?

A steep rise in short interest was recorded in Atara Biotherapeutics Inc. stocks on Aug 14, 2023, dropping by -0.43 million shares to a total of 12.19 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 12.62 million shares. There was a decline of -3.53%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 12.37% of the overall stock float, the days-to-cover ratio (short ratio) fell to 10.41.

According to FactSet, Atara Biotherapeutics Inc.’s share price will average $16.19 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1308.45 percent from its previous closing price of $1.42. Analysts expect Atara Biotherapeutics Inc. stock to reach the higher price of $31.00, while the lowest price estimate is $1.40. However, 10 analysts have rated ATRA stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here